OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 116 filers reported holding OCULAR THERAPEUTIX INC in Q4 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $92,261 | -51.0% | 17,880 | -50.0% | 0.00% | -50.0% |
| Q1 2023 | $188,455 | +87.5% | 35,760 | 0.0% | 0.00% | +100.0% |
| Q4 2022 | $100,486 | -49.0% | 35,760 | -24.5% | 0.00% | -60.0% |
| Q3 2022 | $197,000 | -78.4% | 47,381 | -48.0% | 0.01% | -80.0% |
| Q3 2021 | $912,000 | -50.2% | 91,166 | -29.5% | 0.02% | -57.6% |
| Q2 2021 | $1,832,000 | +164.7% | 129,225 | +206.4% | 0.06% | +126.9% |
| Q1 2021 | $692,000 | -51.4% | 42,177 | -38.7% | 0.03% | -50.9% |
| Q4 2020 | $1,425,000 | +9.0% | 68,846 | -59.9% | 0.05% | -32.9% |
| Q3 2020 | $1,307,000 | -37.4% | 171,735 | -31.5% | 0.08% | -44.8% |
| Q2 2020 | $2,088,000 | +127.0% | 250,712 | +34.8% | 0.14% | +88.2% |
| Q1 2020 | $920,000 | +161.4% | 185,949 | +108.8% | 0.08% | +145.2% |
| Q4 2019 | $352,000 | +28.0% | 89,077 | -1.6% | 0.03% | +24.0% |
| Q3 2019 | $275,000 | +276.7% | 90,527 | +446.6% | 0.02% | +257.1% |
| Q2 2019 | $73,000 | -85.5% | 16,561 | -69.4% | 0.01% | -93.3% |
| Q2 2017 | $502,000 | – | 54,200 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
| Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
| DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
| Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
| Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
| Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
| Covestor Ltd | 60,008 | $316 | 0.28% |
| Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
| EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
| Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |